Compare HESM & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HESM | TVTX |
|---|---|---|
| Founded | 2014 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 5.3B |
| IPO Year | 2019 | 2013 |
| Metric | HESM | TVTX |
|---|---|---|
| Price | $38.08 | $59.62 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 13 |
| Target Price | ★ $41.00 | $40.62 |
| AVG Volume (30 Days) | 1.2M | ★ 1.4M |
| Earning Date | 05-04-2026 | 05-04-2026 |
| Dividend Yield | ★ 8.13% | N/A |
| EPS Growth | N/A | ★ 92.89 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,621,300,000.00 | N/A |
| Revenue This Year | $1.59 | $44.76 |
| Revenue Next Year | $3.10 | $35.51 |
| P/E Ratio | $13.07 | ★ N/A |
| Revenue Growth | ★ 8.41 | N/A |
| 52 Week Low | $31.63 | $22.06 |
| 52 Week High | $41.44 | $68.73 |
| Indicator | HESM | TVTX |
|---|---|---|
| Relative Strength Index (RSI) | 34.05 | 38.69 |
| Support Level | $36.74 | $53.76 |
| Resistance Level | $40.37 | $59.93 |
| Average True Range (ATR) | 0.83 | 2.57 |
| MACD | -0.21 | -0.88 |
| Stochastic Oscillator | 7.99 | 13.50 |
Hess Midstream LP is a fee-based, growth-oriented limited partnership that owns, operates, develops, and acquires a portfolio of midstream assets. The company provides fee-based services to Chevron Corporation and generates all of its revenue by charging fees for gathering, compressing, and processing natural gas, fractionating NGLs, gathering, terminaling, loading, and transporting crude oil and NGLs, storing and terminaling propane, and gathering and disposing of produced water. It operates through gathering, processing, and storage, and terminaling and export segments, with the gathering segment contributing the maximum share of revenue and comprising natural gas gathering and compression, as well as crude oil gathering and produced water gathering and disposal assets.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.